Latest News and Press Releases
Want to stay updated on the latest news?
-
Preliminary Total Revenue for Q2 2022 was approximately $1.0 millionCash as of June 30, 2022 was approximately $16.6 millionFirst commercial customer contract for Acuitas AMR Gene Panel signed in June...
-
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of pathogens by Unyvero HPNAdditional pathogens...
-
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000th prospective patient sampleFourth trial site added to optimize enrollment for different sample types and accelerate trial...
-
Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term Leader Life Sciences to seek regulatory...
-
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic...
-
Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., May ...
-
ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
-
ROCKVILLE, Md., April 25, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
-
OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
ROCKVILLE, Md., April 20, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
-
Extended existing master services agreement with Sandoz, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening focus on...